title: Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
abstract: OBJECTIVE
  To evaluate the efficacy of temozolomide (TMZ) combined with cisplatin (CDDP) in terms of response rate, time to progression (TTP) and overall survival (OS), as well as the tolerability of the regimen in patients with brain metastases from solid tumors.
  
  
  METHODS
  Patients (n=32) with brain metastases were treated with TMZ 150 mg/m2/day (chemotherapy-pretreated) or 200 mg/m2/day (chemotherapy-naive) for 5 days, combined with CDDP 75 mg/m2 on day 1, every 28 days. Primary tumor sites included breast cancer (n=15), lung cancer (n=12) and other (n=5). Twenty-seven patients had received prior chemotherapy for extracranial disease and 17 had prior radiotherapy to the brain.
  
  
  RESULTS
  One patient (3.1%) with non-small cell lung cancer (NSCLC) achieved complete response. Nine patients (28.1%; six with breast cancer, two with melanoma and one with NSCLC) achieved a partial response and five patients (16%) had stable disease. Median OS was 5.5 months and median TTP 2.9 months. One patient died from septicemia/neutropenic fever. Grade III-IV toxicities included anemia (9%), leukopenia (6%), thrombocytopenia (3%), renal toxicity (3%), headache (3%), fatigue (3%), nausea (3%), vomiting (3%), and alopecia (6%).
  
  
  CONCLUSIONS
  TMZ combined with CDDP is an active and well-tolerated combination in patients with brain metastases from solid tumors.
authors.affiliation: Henry Dunant Hospital, Athens, Greece. hecogiat@otenet.gr
authors.forename: Christos
authors.initials: C
authors.lastname: Christodoulou
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Bafaloukos
authors.forename: Helen
authors.initials: H
authors.lastname: Linardou
authors.forename: Gerassimos
authors.initials: G
authors.lastname: Aravantinos
authors.forename: Aristotelis
authors.initials: A
authors.lastname: Bamias
authors.forename: Maria
authors.initials: M
authors.lastname: Carina
authors.forename: George
authors.initials: G
authors.lastname: Klouvas
authors.forename: Dimosthenis
authors.initials: D
authors.lastname: Skarlos
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D003606:Dacarbazine; D002945:Cisplatin; D000077204:Temozolomide
references.citation: Ann Oncol. 2001 Feb;12 (2):249-54
references.pmid: 11300333
references.citation: Carcinogenesis. 1989 Sep;10(9):1681-4
references.pmid: 2766459
references.citation: Neurosurg Clin N Am. 1996 Jul;7(3):337-44
references.pmid: 8823767
references.citation: Cancer. 1997 Nov 1;80(9):1746-54
references.pmid: 9351543
references.citation: J Chemother. 1995 Jun;7(3):224-9
references.pmid: 7562019
references.citation: Clin Cancer Res. 1999 Jul;5(7):1629-37
references.pmid: 10430061
references.citation: Control Clin Trials. 1989 Mar;10(1):1-10
references.pmid: 2702835
references.citation: J Clin Oncol. 1989 Jul;7(7):916-22
references.pmid: 2544685
references.citation: Cancer Res. 1982 Jun;42(6):2474-9
references.pmid: 6280860
references.citation: J Clin Oncol. 1999 Sep;17 (9):2762-71
references.pmid: 10561351
references.citation: Lung Cancer. 1998 May;20(2):85-91
references.pmid: 9711526
references.citation: Eur J Cancer. 1999 Apr;35(4):580-5
references.pmid: 10492631
references.citation: J Neurooncol. 2001 Jul;53(3):259-65
references.pmid: 11718258
references.citation: J Pharmacol Exp Ther. 2000 Aug;294(2):664-71
references.pmid: 10900246
references.citation: Clin Cancer Res. 1999 Feb;5(2):309-17
references.pmid: 10037179
references.citation: Cancer. 1999 Apr 1;85(7):1599-605
references.pmid: 10193952
references.citation: Cancer. 1996 Oct 15;78(8):1781-8
references.pmid: 8859192
references.citation: J Clin Oncol. 2000 Jan;18(1):158-66
references.pmid: 10623706
references.citation: Cancer. 1992 Feb 15;69(4):972-80
references.pmid: 1735089
references.citation: Oncology. 1996 May-Jun;53(3):210-3
references.pmid: 8643223
references.citation: Lung Cancer. 1998 May;20(2):81-4
references.pmid: 9711525
references.citation: Ann Med. 1998 Jun;30(3):296-9
references.pmid: 9677016
references.citation: Clin Cancer Res. 1997 Oct;3(10 ):1769-74
references.pmid: 9815562